This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

MarketVIEW: Cytomegalovirus Vaccines

NEW YORK, Feb. 18, 2013 announces that a new market research report is available in its catalogue:

MarketVIEW: Cytomegalovirus vaccines

Cytomegalovirus (CMV) is a member of the herpesvirus family and is widely prevalent throughout the population. In the US around 50-80% of adults are infected by 40 years of age (US CDC figures) whereas in other parts of the world, especially developing countries, prevalence is much higher even at younger ages. Usually CMV infections are dormant causing no significant health issues, however, in certain populations with a weakened immune system e.g. HIV, transplants (HSCT) the virus can reactivate can cause disease e.g. pneumonia. CMV infection is also a concern in the neonate after transmission from a pregnant women pre or post partum. Approximately 1 in 150 children is born with a congenital CMV infection and 1 in 750 born with permanent disabilities due to the virus. 

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Cytomegalovirus vaccines (TX + PX approaches) across major Western and emerging markets to 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon the level of populations targeted, which in turn are influenced by vaccine mechanism of action and vaccinee serostatus. 


Executive summaryCMV preconception vaccine: available market ($000s) to 2035CMV transplant vaccine: available market ($000s) to 2035CMV preconception vaccine: demand (000s doses) to 2035CMV transplant vaccine: demand (000s doses) to 2035CMV vaccine: modelling assumptions/rationaleThe role of CMV vaccine(s)Target populations: CMV preconception vaccineTarget populations: CMV transplant vaccineTarget groups by serological risk profilePricing: CMV preconception vaccinePricing: CMV transplant vaccineTarget product profile: CMV preconception vaccineTarget product profile: CMV transplant vaccineKey commercial model assumptions: preconception vaccineKey commercial model assumptions: transplant vaccineMarkets included in the modelModel forecast comparisons: June 2010 v currentCMV vaccines: R&D pipelineCompetitor landscape: overviewVical/Astellas: TransVax and CyMVectinGSK: preconception CMV vaccineNovartis/AlphaVax: alphavirus replicon CMV vaccineSanofi Pasteur: CMV gB vaccineOther vaccine candidatesVaccine pipeline summaryEstimated launch datesCMV: review of current epidemiologyEpidemiology: transplantsEpidemiology: congenital CMV infectionMethodology: HSCTs populations (by age and serostatus)Methodology: solid organ transplant populations (by age and serostatus)Methodology: preconception vaccinePreconception vaccine: comparison of "low" versus "high" coverage scenariosReferences/bibliographyAbout VacZine AnalyticsDisclaimerPAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model (MS Excel-based)Title sheetScenarion definitionsGRAND SUMMARY CHARTSCHARTS VALUECHARTS VOLUMECHARTS VOLUME – HIGHVALUE SUMMARYVOLUME SUMMARYPreconception vaccine - femalesCountry volume/population sheetsUSCanadaUKGermanyFranceSpainItalyOther EUJapanTransplant vaccine - femalesCountry volume/population sheetsUSCanadaUKGermanyFranceSpainItalyOther EUJapanSource materialHSCTs by serostatusForecast HSCTsForecast HSCTsKidney and Liver TX baseForecast Kidney TXForecast liver TxSOT by serostatusPopulationsBack pageAbout VacZine AnalyticsDisclaimer

To order this report:: MarketVIEW: Cytomegalovirus vaccines

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs